Direction
Buy
Sell
Types
LMT Order
Price
QTY
Amount
--
MLTX MoonLake Immunotherapeutics
12.0500.0000.00%
Close
02/03 16:00 ET
12.0500.0000.00%
Post Mkt Price 02/03 16:45 ET
High
12.250
Open
11.970
Turnover
1.02M
Low
11.700
Pre Close
12.050
Volume
84.62K
Post-Market
5D
1D
1W
1M
1Q
1Y
Price Forecast
News
Comment
MoonLake Immunotherapeutics (NASDAQ:MLTX) Receives Buy Rating From HC Wainwright
MoonLake Immunotherapeutics (NASDAQ:MLTX – Get Rating)'s stock had its "buy" rating reiterated by research analysts at HC Wainwright in a research report issued to clients and investors on Friday, Be
MoonLake Immunotherap Price Target Maintained With a $28.00/Share by HC Wainwright & Co.
MoonLake Immunotherap Price Target Maintained With a $28.00/Share by HC Wainwright & Co.
H.C. Wainwright Reaffirms Their Buy Rating on MoonLake Immunotherapeutics (MLTX)
MoonLake Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 02/03/2023 131.31% HC Wainwright & Co. → $28 Reiterates → Buy 11/11/2022 32.18% Jefferies → $16 Initiates
HC Wainwright & Co. Reiterates Buy on MoonLake, Maintains $28 Price Target
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates MoonLake with a Buy and maintains $28 price target.
MoonLake Completes Patient Enrollment in Phase 2 Trial of Nanobody Sonelokimab
MoonLake Immunotherapeutics Completes Patient Enrollment and Randomization Ahead of Schedule in a Phase 2 Trial of the Nanobody® Sonelokimab in Moderate-to-severe Hidradenitis Suppurativa
MoonLake Immunotherapeutics completes patient enrollment and randomization ahead of schedule in a Phase 2 trial of the Nanobody®sonelokimab in moderate-to-severe hidradenitis suppurativa Enrollment ta
MoonLake Immunotherapeutics Initiated With a Buy at Bryan Garnier
MoonLake Immunotherapeutics (NASDAQ:MLTX) Trading Down 6.5%
Shares of MoonLake Immunotherapeutics (NASDAQ:MLTX – Get Rating) fell 6.5% on Monday . The stock traded as low as $10.50 and last traded at $10.50. 5,786 shares were traded during mid-day trading, a
MoonLake Immunotherapeutics (NASDAQ:MLTX) Given Average Rating of "Buy" by Brokerages
Shares of MoonLake Immunotherapeutics (NASDAQ:MLTX – Get Rating) have earned an average rating of "Buy" from the six brokerages that are currently covering the firm, Marketbeat Ratings reports. Six
Company Overview
More
Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.
CEO： Dr. Jorge Santos da Silva
Market： NASDAQ
Listing Date： 10/20/2020
Paper Trade
More
Hot List
TradeSearchNews
SymbolLatest price%Chg
Loading...
Watchlist
No Stock Yet